南宫NG28(中国)

Be the most trusted biotech company

2026-06-02

Featured in Both The Lancet and ASCO: Henlius’ Serplulimab Pioneers a New Perioperative Chemotherapy-Sparring Regimen for Gastric Cancer
2026-05-31

ASCO 2026 | Henlius Accelerates Global Development of Its PD-L1 ADC, Demonstrating Promising Activity Across Multiple Difficult-to-Treat NSCLC Subgroups and Potential for Earlier-Line Development
2026-05-29

Henlius' Pertuzumab Approved in China, Solidifying Breast Cancer Strategy as the First China-US-EU Approved Chinese Trastuzumab-Pertuzumab Combination
2026-05-28

Henlius Advances Global Development of PD-L1 ADC HLX43 as Phase 2/3 MRCT in Previously Treated Advanced sqNSCLC Completes First Patient Dosed in China
2026-05-26

Globalisation 2.0 | First Patient Dosed in China for International Multi-centre Phase 1 Clinical Trial of Henlius’ Subcutaneous Daratumumab Biosimilar HLX15-SC
2026-05-26

Globalisation 2.0 | Henlius Completes First Patient Dosed in China for MRCT of pimurutamab (HLX07) Plus serplulimab, Accelerating Global Development
2026-05-25

ASCO 2026 | Henlius to Disclose Key PFS Data of PD-L1 ADC HLX43 for the First Time; Clinical Benefits in Refractory NSCLC to be Unveiled
2026-05-23

Henlius' Serplulimab Receives Positive CHMP Opinion for the Treatment of sqNSCLC
2026-05-23

Henlius' First-in-Class B7-H3–Targeted Sialidase Fusion Protein HLX316/E-688 Administered to First Patient in Phase 1 Study in China